ArriVent licenses ADC from $100M biobuck deal with Aarvik

CAR-T Digest - August 2020

15 Aug 2024: ArriVent licenses ADC from $100M biobuck deal with Aarvik

ArriVent BioPharma has licensed an antibody-drug conjugate (ADC) from Aarvik Therapeutics, following a $100 million deal from December 2021
Under the original agreement, Aarvik handled discovery and preclinical development, with ArriVent set to take over at human trials
Aarvik received a combination of research funding, option fees, milestone payments, and royalties, but the exact upfront payment was not disclosed
Aarvik’s ADC, developed using advanced protein engineering technologies, targets difficult oncology indications
ArriVent, which raised $175 million in an IPO, focuses on bringing China-developed drugs to Western markets, including the rights to furmonertinib from Allist Pharmaceuticals